enGene Therapeutics Inc. Operating Expenses
enGene Therapeutics Inc. (ENGN) reported Operating Expenses of $34.01 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-08
- enGene Therapeutics Inc. operating expenses for the quarter ending 2026-07-31 was $34.01M, a 13.58% increase year-over-year.
- enGene Therapeutics Inc. operating expenses for the quarter ending 2026-04-30 was $31.97M, a 17.86% increase year-over-year.
- enGene Therapeutics Inc. operating expenses for the quarter ending 2026-01-31 was $31.18M, a 17.18% increase year-over-year.
- enGene Therapeutics Inc. operating expenses for the quarter ending 2025-10-31 was $39.48M, a 126.19% increase year-over-year.
- enGene Therapeutics Inc. operating expenses for fiscal 2025 was $123.17M, a 97.71% increase from fiscal 2024.
- enGene Therapeutics Inc. operating expenses for fiscal 2024 was $62.30M, a 139.05% increase from fiscal 2023.
- enGene Therapeutics Inc. operating expenses for fiscal 2023 was $26.06M, a 34.14% increase from fiscal 2022.
- enGene Therapeutics Inc. operating expenses for fiscal 2022 was $19.43M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-07-31 | $34.01M 10-Q · filed 2026-09-08 | $65.98M derived: sum of 2 quarters · filed 2026-09-08 | $97.17M 10-Q · filed 2026-09-08 | $136.65M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | $31.97M 10-Q · filed 2026-06-15 | $63.15M 10-Q · filed 2026-06-15 | $102.63M derived: sum of 3 quarters · filed 2026-06-15 | $132.58M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | $31.18M 10-Q · filed 2026-03-09 | $70.67M derived: sum of 2 quarters · filed 2026-03-09 | $100.61M derived: sum of 3 quarters · filed 2026-09-08 | $127.74M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | $39.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $69.43M derived: sum of 2 quarters · filed 2026-09-08 | $96.55M derived: sum of 3 quarters · filed 2026-09-08 | $123.17M 10-K · filed 2025-12-22 |
| 2025-07-31 | $29.95M 10-Q · filed 2026-09-08 | $57.07M derived: sum of 2 quarters · filed 2026-09-08 | $83.68M 10-Q · filed 2026-09-08 | $101.14M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | $27.12M 10-Q · filed 2026-06-15 | $53.74M 10-Q · filed 2026-06-15 | $71.19M derived: sum of 3 quarters · filed 2026-06-15 | $87.95M derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | $26.61M 10-Q · filed 2026-03-09 | $44.07M derived: sum of 2 quarters · filed 2026-03-09 | $60.83M derived: sum of 3 quarters · filed 2026-03-09 | $78.14M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | $17.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $34.21M derived: sum of 2 quarters · filed 2025-12-22 | $51.52M derived: sum of 3 quarters · filed 2025-12-22 | $62.30M 10-K · filed 2025-12-22 |
| 2024-07-31 | $16.76M 10-Q · filed 2025-09-11 | $34.07M derived: sum of 2 quarters · filed 2025-09-11 | $44.84M 10-Q · filed 2025-09-11 | $55.28M derived: sum of 4 quarters · filed 2025-09-11 |
| 2024-04-30 | $17.31M 10-Q · filed 2025-06-12 | $28.08M 10-Q · filed 2025-06-12 | $38.52M derived: sum of 3 quarters · filed 2025-06-12 | $44.77M derived: sum of 4 quarters · filed 2025-06-12 |
| 2024-01-31 | $10.77M 10-Q · filed 2025-03-10 | $21.21M derived: sum of 2 quarters · filed 2025-03-10 | $27.46M derived: sum of 3 quarters · filed 2025-03-10 | $32.20M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | $10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | $16.69M derived: sum of 2 quarters · filed 2024-12-19 | $21.43M derived: sum of 3 quarters · filed 2024-12-19 | $26.06M 10-K · filed 2024-12-19 |
| 2023-07-31 | $6.25M 10-Q · filed 2024-09-10 | $10.98M derived: sum of 2 quarters · filed 2024-09-10 | $15.62M 10-Q · filed 2024-09-10 | |
| 2023-04-30 | $4.74M 10-Q · filed 2024-06-14 | $9.37M 10-Q · filed 2024-06-14 | ||
| 2023-01-31 | $4.63M 10-Q · filed 2024-03-11 | |||
| 2022-10-31 | $19.43M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |